Published in J Am Coll Cardiol on February 20, 2007
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology (2009) 1.16
Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol (2013) 1.00
Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol (2010) 0.85
Decreased left ventricular distensibility in response to postural change in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol (2010) 0.84
Principles of transthoracic echocardiographic evaluation. Nat Rev Cardiol (2015) 0.80
Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia. J Saudi Heart Assoc (2012) 0.79
Cell- and molecular-level mechanisms contributing to diastolic dysfunction in HFpEF. J Appl Physiol (1985) (2015) 0.75
The clinical quandary of left and right ventricular diastolic dysfunction and diastolic heart failure. Cardiovasc J Afr (2010) 0.75
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
Systolic and diastolic mechanics in stress cardiomyopathy. Circulation (2014) 3.36
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail (2005) 3.26
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol (2008) 2.66
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol (2006) 2.58
Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation (2005) 2.31
Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation (2006) 2.11
Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. Radiology (2014) 2.09
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail (2011) 1.93
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med (2004) 1.67
Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol (2011) 1.66
Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol (2003) 1.60
Chronic heart failure reduces Akt phosphorylation in human skeletal muscle: relationship to muscle size and function. J Appl Physiol (1985) (2010) 1.59
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail (2012) 1.54
Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol (2009) 1.50
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail (2015) 1.49
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail (2012) 1.46
Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant (2007) 1.45
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation (2008) 1.45
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
Chronic heart failure: a report from the Dartmouth Diastole Discourses. Congest Heart Fail (2006) 1.44
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail (2012) 1.43
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol (2009) 1.41
Cardiac-specific expression and hypertrophic upregulation of the feline Na(+)-Ca(2+) exchanger gene H1-promoter in a transgenic mouse model. Circ Res (2002) 1.35
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail (2010) 1.29
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail (2008) 1.28
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J Clin Invest (2012) 1.25
Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2011) 1.22
Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J (2009) 1.19
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol (2003) 1.15
Mechanisms underlying skeletal muscle weakness in human heart failure: alterations in single fiber myosin protein content and function. Circ Heart Fail (2009) 1.13
Quantification of protein expression changes in the aging left ventricle of Rattus norvegicus. J Proteome Res (2009) 1.13
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
A multidimensional proteomic approach to identify hypertrophy-associated proteins. Proteomics (2006) 1.04
New molecular mechanism in diastolic heart failure. Circulation (2006) 1.02
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol (2006) 1.00
Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. Am J Cardiol (2008) 1.00
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res (2003) 1.00
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol (2002) 1.00
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci (2008) 0.96
Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail (2014) 0.96
A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. Am J Physiol Heart Circ Physiol (2008) 0.95
Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg (2002) 0.95
Cardiac myosin isoforms exhibit differential rates of MgADP release and MgATP binding detected by myocardial viscoelasticity. J Mol Cell Cardiol (2012) 0.95
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail (2012) 0.94
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation (2005) 0.93
In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol (2008) 0.93
Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. Am J Physiol Heart Circ Physiol (2003) 0.93
Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload. J Mol Cell Cardiol (2007) 0.91
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail (2014) 0.90
Regulation of Ncx1 expression. Identification of regulatory elements mediating cardiac-specific expression and up-regulation. J Biol Chem (2006) 0.90
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg (2011) 0.90
Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 0.90
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens (2011) 0.89
Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. Am J Physiol Heart Circ Physiol (2012) 0.89
Intracellular distributions of essential elements in cardiomyocytes. J Struct Biol (2006) 0.89
A novel tubular scaffold for cardiovascular tissue engineering. Tissue Eng (2004) 0.89
Abnormal calcium homeostasis: one mechanism in diastolic heart failure. J Am Coll Cardiol (2011) 0.89
Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. Am J Physiol Heart Circ Physiol (2011) 0.89
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J (2013) 0.89
Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. Am J Cardiol (2006) 0.88
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail (2014) 0.87
In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). Am J Cardiol (2012) 0.87
Skeletal muscle myofibrillar mRNA expression in heart failure: relationship to local and circulating hormones. J Appl Physiol (1985) (2005) 0.86
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail (2011) 0.86
Lack of relationship between Doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure. Am Heart J (2004) 0.86
Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness. Am J Physiol Heart Circ Physiol (2002) 0.85
Titin: an endosarcomeric protein that modulates myocardial stiffness in DCM. J Card Fail (2002) 0.85
Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail (2010) 0.85
Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol (2010) 0.85
Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol (2012) 0.85
Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. J Card Fail (2011) 0.84
β3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS One (2012) 0.84
Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail (2012) 0.83
Genes overexpressed in cerebral arteries following salt-induced hypertensive disease are regulated by angiotensin II, JunB, and CREB. Am J Physiol Heart Circ Physiol (2007) 0.82
Comparison of variability associated with sample preparation in two-dimensional gel electrophoresis of cardiac tissue. J Biomol Tech (2006) 0.82
Elevated rates of force development and MgATP binding in F764L and S532P myosin mutations causing dilated cardiomyopathy. J Mol Cell Cardiol (2013) 0.81
Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J (2012) 0.81
Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol (2008) 0.81
Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens (2013) 0.81
Acto-myosin crossbridge kinetics in humans with coronary artery disease: influence of sex and diabetes mellitus. J Mol Cell Cardiol (2005) 0.80
Coronary venous capture of contrast during angiography. J Interv Cardiol (2006) 0.80
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail (2005) 0.80
HFpEF: cardiovascular abnormalities not just comorbidities. Circ Heart Fail (2012) 0.80
Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant (2005) 0.79